Human Pappilomavirus (HPV) induced cancers and prevention by immunization

Pakistan Journal of Pharmaceutical Sciences

Volumn 25, Issue 4, 2012, Pages 763-772

  Khaliq, Sheikh Abdul ^a   Naqvi, Syed Baqir Shyum ^b   Fatima, Anab ^a  

^a HAMDARD UNIVERSITY   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Adsorbent; Bivalent; Booster dose; Cancer cost; Cancer incidences; Cost burden; HPV; Low risk HPV; Memory B cells; Pappilomatosis; QALY; Quadrivalent; RDNA technology; Screening; Serotypes; Society; Vaccines

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

ALPHAPAPILLOMAVIRUS; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; CONDYLOMA ACUMINATUM; CROSS PROTECTION; DEVELOPING COUNTRY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FOLLOW UP; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS INDUCED CANCER; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 13; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNOLOGICAL MEMORY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALAISE; MEMORY CELL; MULTICENTER STUDY (TOPIC); PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; SEROCONVERSION; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; FEMALE; IMMUNIZATION; IMMUNOLOGY; INCIDENCE; MALE; NEOPLASM; PAKISTAN; PAPILLOMA VIRUS; RISK ASSESSMENT; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; FEMALE; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INCIDENCE; MALE; NEOPLASMS; PAKISTAN; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK ASSESSMENT; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84871902451     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Adolescents Study Investigators Network (2010). Immunogenicity and safety of human papillomavirus- 16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanusacellular pertussis-inactivated poliovirus vaccine to girls and young women. J. Adolesc. Health, 46: 142-151.
2. Anhang R, Goodman A and Goldie SJ (2004). HPV communication: Review of existing research and recommendations for patient education. CA Cancer J. Clin., 54: 248-259.
3. Ault KA (2007). Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: A combined analysis of four randomized clinical trials. Lancet, 369: 1861-1868.
4. Block SL, Nolan T, Sattler C, Barr E, Giacoletti K, Marchant C, Castellsague X, Rusche S, Lukac S, Bryan J, Cavanaugh P, Reisinger K. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118: 2135-2145.
5. Bonnez W (2002). In: Richman DD, Whitley RJ, Hayden FJ. Cervical cancer and huma pappiloma virus related disease: Epidemiology and clinical burden. American Society for Microbiology Press; Washington, DC, pp. 557-596.
6. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. (2000). Comparison of human pappiloma virus types 16, 18 and 6 capsid antibody responses following incident infection. J. Infect. Dis., 181: 1911-1919.
7. Castle PE (2004). Beyond human pappiloma virus: The cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J. Low Genital. Tract. Dis., 8: 224-230.
8. Chesson HW, Ekwueme DU, Saraiya M and Markowitz LE (2008). Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis., 14: 244-251.
9. Elbasha EH, Dasbach EJ and Insinga RP (2007). Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis., 13: 28-41.
10. Fairley CK, Gay NJ, Forbes A, Abramson M and Garland SM (1995). Hand genital transmission of genital warts? An analysis of prevalence data. Epidemiol. Infect., 115: 169-176.
11. Ferenczy A, Bergeron C and Richart RM (1989). Human pappilomavirus DNA in fomites on objects use for the management of patient with genital human pappiloma virus infection. Obstet. Gynecol., 74: 950-954.
12. Franco EL, Cuzick J, Hildesheim A and Sanjose S (2006). Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine, 24(Suppl. 3): S171-S177.
13. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Singhs HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med., 356: 1928-1943.
14. GlaxoSmithKline (2009). Bivalent Vaccine (human papillomavirus bivalent vaccine, recombinant intramuscular injection) product information. Research Triangle Park, NC.
15. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst., 96: 604-615.
16. Harper D, Gall S, Naud P, Quint W, Dubin G and Jenkins D (2008). Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Longterm follow up through 6.4 years in women vaccinated with Bivalent Vaccine (GSK's HPV 16/18 AS04 candidate vaccine). Presented at the 39th annual meeting on women's cancer of the Society of Gynecologic Oncologists, Tampa, FL.
17. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA and Dubin G (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367: 1247-1255.
18. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A, Sanchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer CJ, Viscidi R, Munoz N and Franceschi S (2003). Human pappilomavirus and oral cancer: The international agency for research on cancer multi center study. J. Natl. Cancer Inst., 95: 1772-1783.
19. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE and Lowy DR. (2007). Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial. JAMA, 298: 743-753.
20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. (1998). Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med., 338: 423-428.
21. Howley PM and Lowy DR (2001). In: Knipe DM; Pappiloma virus and their replication. Philadelphia, Pa: Lippincott-Raven, pp. 2197-2229.
22. HPV Vaccine Study Investigators for Adult Women (2007). Human papillomavirus (HPV) 16/18 l1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years. J. Clin. Oncol., 25(20 Suppl): 3007.
23. Jansen KU and Shaw AR (2004). Human Pappilomavirus vaccines and prevention of cervical cancer. Annu. Rev. Med., 55: 319-331.
24. Jayaprakash V, Reid M, Hatton E, Merzianu M, Rigual N, Marshall J, Gill S, Frustino J, Wilding G, Loree T, Popat S, Sullivan M (2011). Human pappilomavirus type 16 and 18 in epithelial dysplasia of oral cavity and oropharynx, a meta analysis; 1985-2010. Oral Oncology, 47(11): 1048-1054.
25. Kidon MI, Shechter E and Toubi E (2011). Vaccination against human papilloma virus and cervical cancer, Harefuah, 150(1): 33-6,68. Affiliation; Allergy and Clinical Immunoelogy, Sheba Medical Center, Tel Hashomer.
26. Kim JJ and Goldie SJ (2008). Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med., 359: 821-832.
27. Kim JJ and Goldie SJ (2009). Cost-effectiveness analysis of including boys in a human papillomavirum vaccination programme in the United States. BMJ; 339:b3884. Available from http://www.bmj.com/content/339/bmj.b3884.long.
28. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR and Meijer CL (2001). High risk human pappiloma virus is sexually transmitted: Evidence from a follow up study of virgins starting sexual activity. Cancer Epidemiol Biomarkers Prev., 10: 101-106.
29. Manhart LE and Koutsky LA (2002). Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta analysis. Sex Transm. Dis., 29: 725-735.
30. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU and Barr E (2006). Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet. Gynecol., 107: 18-27.
31. Merck & Co. Inc. (2009). Quadrivalent Vaccine (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant suspension for intramuscular injection) product information. Whitehouse Station, NJ.
32. Moscicki AB (1999). Human pappiloma virus infections in adolescence. Pediatr. Clin. North. Am., 46: 783-807.
33. Moscicki AB. (2008) HPV vaccines: Today and in the future. J. Adol. Health, 43: S26-S40.
34. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S and Moscicki AB (2002). Time course of humoral, and cell mediated immune responses to human pappiloma virus type 16 in infected women. Clin. Diagn. Lab. Immunol., 9: 877-882.
35. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hove J, Steinwall M, Riis- Johannessen G, Andersson-Ellstrom A, Elfgren K, Von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ and Barr E (2007). Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine, 25: 4931-4939.
36. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamram U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. (2009). Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet, 374: 301-314.
37. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G. (2007). Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health, 40: 564-571.
38. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. (2007). Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J., 26: 201-209.
39. Roden RBS, Lowy DR and Schiller JT (1997). Pappiloma virus is resistant to dessication. J. Infect. Dis., 176: 1076-1079.
40. Sanaullah G, Ishrat Bukhari S, Haroon A, Javeid I (2010). Carcinoma Uterine Cervix. Pak. Jour. of Pharmacol., 27(2): 37-42.
41. Sataiya M, Ahmed F, Krishnan S, Richard TB, Unger ER, Lawson HW. (2007). Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet. Gynecol., 109: 360-370.
42. Schiffman M and Castle PE (2005). The promise of global cervical-cancer prevention. N. Engl. J. Med., 353: 2101-2104.
43. Schmiedeskamp MR and Kockler DR (2006). Human papillomavirus vaccines. Ann. Pharmacother., 40: 1344-1352.
44. Schwarz TF (2006). An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. J. Clin. Oncol., 24(20 Suppl): 1008.
45. Smith EM, Ritchie JM, Yankowitz J, Swarnavel S, Wang D, Haugen TH and Turek LP (2004). Human pappilomavirus prevalence and types in newborns and parents: concordance and mode of transmission. Sex Transm. Dis., 31: 57-62.
46. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR and Bryan JT (2007). Antibodies from women immunized with Quadrivalent Vaccine cross-neutralize HPV 45 pseudovirions. Hum. Vaccin., 3: 109-115.
47. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. (2009). Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet. Gynecol., 13: 917-924.
48. Stanley M (2006). Immune responses to human papillomavirus. Vaccine, 24: S16-S22.
49. The FUTURE II Study Group (2007). Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J. Infect. Dis., 196(10): 1438-1446.
50. The FUTURE II Study Group (2007). Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N. Engl. J. Med., 356: 1915-1927.
51. Tindle RW (2002). Immune evasion in human pappiloma virus associated cervical cancer. Nat. Rev. Cancer, 2: 1-7.
52. US Food and Drug Administration (2009). News release: FDA approves new indication for Quadrivalent Vaccine to prevent genital warts in men and boys, Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ ucm187003.ht m. Accessed February 10, 2010.
53. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ and Barr E (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine, 24: 5571-5583.
54. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ and Barr E (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol., 6: 271-278.
55. Walboomers JM, Jacobs MV, Manos MM, Xavier F, Bosch J, Alain Kummer, Keerti V Shah, Peter JF Snijders, Julian Peto, Chris JLM Meijer and Nubia Munoz (1999). Human pappiloma virus is necessary cause of invasive cervical cancer worldwide. J. Pathol., 189: 12-19.
56. Wang SS and Hildesheim A (2003). Viral and host factor in human pappiloma virus persistence and progression. J. Natl. Cancer Inst. Mongr., 31: 35-40.
57. Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK, Richards TB, (2008). Using population based cancer registry data to assess the burden of human pappiloma virus associated cancers in the United States, overview of methods. Cancer, 113(10 Suppl.): 2841-2854.
58. Weinstock H, Berman S and Cates W Jr. (2004). Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod. Health, 36: 6-10.
59. Welters MJ, de Jong A, van den Eeden SJ, Van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R and Van der Burg SH (2003). Frequently display of human pappiloma virus type 16 E-6 specific memory t-helper cells in the healthy population as witness of previous viral encounter. Cancer Res., 63: 636-641.
60. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB and Koutsky LA (2003). Genital human pappiloma virus infection: incidence and risk factors in a cohort of female university student. Am. J. Epidemiol., 157: 218-226.
61. Yasmin B, Asif B, Sania N, Ashfaq A, Ahmed U, Shahid P, Rashida A, Naila K, Ahmed R, Hadi B, Imtiaz B and Sheema H (2006) Pakistan - Country Profile of Cancer and Cancer Control. J. Pak. Med. Assoc., 56(3): 2006.